Evidence map›Paper›PMID 41079080›Full record

ArticleFrontiers in oncology2025

Next-generation sequencing reveals clinical features and prognosis of gene mutations in Chinese children with T-cell acute lymphoblastic leukaemia.

Senlin Zhang, Xinran Chu, Zhiheng Li, Qi Ji, Na Meng, Wei Gao, Xiao Zhang, Yixin Hu, Li Gao, Bohan Li and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Senlin Zhang *Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China.
Xinran Chu *Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China.
Zhiheng Li *Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China.
Qi Ji *Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China.
Na Meng *Department of Pediatrics, Xinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University, Xinxiang, China.
Wei GaoDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China.
Xiao ZhangDepartment of Hematology, Children's Hospital of Shandong University, Jinan, China.
Yixin HuDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China.
Li GaoDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China.
Bohan LiDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China.
Ping ChenSuzhou Jsuniwell Medical Laboratory, Suzhou, China.
Huihui WanSuzhou Jsuniwell Medical Laboratory, Suzhou, China.
Yu LiuPediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology and Oncology, Shanghai, China.
Yongping ZhangDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China.
Yuanyuan TianJiangsu Pediatric Hematology and Oncology Center, Suzhou, China.
Shuiyan WuHematologic Intensive Care Unit, Children's Hospital of Soochow University, Suzhou, China.
Yizhen LiDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China.
Shaoyan HuDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China.
Hu LiuDepartment of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: The 5-year overall survival (OS) for paediatric T-cell acute lymphoblastic leukaemia (T-ALL) exceeds 80% under the current treatment strategies; however, some patients suffer from treatment failure. Next-generation sequencing (NGS) identified recurrent mutated genes in T-ALL that might affect diagnosis, classification, prognostic stratification, and treatment response. This study aimed to characterise the clinical features and prognosis of gene mutations in paediatric patients with T-ALL. Methods: We enrolled 144 paediatric patients with T-ALL at our centre. Chi-square or Fisher's exact tests were used for categorical variables, and Kaplan-Meier and log-rank tests analysed the survival rates of these patients. Results: The most common mutations were in Conclusion: This study reported the gene mutation spectrum of Chinese paediatric T-ALL, highlighting the role of NGS in molecular classification, risk stratification, and prognosis. Additionally, we emphasised the role of the variant allele frequency of

Indexed as

gene mutationsnext-generation sequencingpaediatricprognosisT-cell acute lymphoblastic leukaemia

Identifiers

PMID41079080
PMCPMC12510939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.